F03125 – Weight Management Trial
We are conducting a clinical research study to test a new medication, Efsubaglutide Alfa (YN-011), for adults who are overweight. The study will look at how well the treatment helps with weight reduction, improves overall health markers, and how safe it is compared to placebo. Participants will receive regular study care and support over about 6 months.
To take part in this study, you need to be between 18 and 75 years old. Eligible participants must either have a BMI of 30 or above, or with a BMI between 27 and 30 along with a weight-related condition such as pre-diabetes, high blood pressure, high cholesterol, fatty liver, osteoarthritis, or sleep apnoea. Participants should not have lost more than 5% of their body weight in the past three months through diet or exercise.
People who join will need to be able to attend study visits, follow the study requirements, and, if applicable, use reliable contraception for the duration of the trial
Eligibility requirements
- Age: 18-75
- Sex: M & F
- BMI: BMI of 30 or higher, or a BMI between 27 and 30 with another weight-related health condition.
- Medication: To take part in this study, you’ll need to avoid using certain medications that could affect your weight or blood sugar. This includes prescription weight-loss drugs (such as Ozempic), glucose-lowering medicines like metformin, and some antidepressants or antipsychotics that may influence weight. Herbal or over-the-counter products for weight loss, including meal replacements, are also not allowed during the study.
- Medical History: If you’ve had weight-loss surgery or procedures like bariatric surgery or liposuction in the past year, or if you plan to have a procedure during the study, you would not be able to join.
Outpatient Visits
- 12 visits including the screening visit
Payment/Remuneration
- You will be reimbursed for your time
How to apply
To register your interest in this trial, please complete the form below, or call us on 1800-FUSION (1800 387 466). A Fusion team member will be in contact to discuss your eligibility shortly.